EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Michael J Hanley iD, Karen Rowland Yeo iD, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan iD, Neeraj Gupta iD

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Michael J Hanley und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Organophosphorus Compounds, Pyrimidines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brigatinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK ‐positive metastatic non‐small cell lung cancer. In vitro studies indicated that brigatinib is primarily metabolized by CYP2C8 and CYP3A4 and inhibits P‐gp, BCRP, OCT1, MATE1, and MATE2K. Clinical drug–drug interaction (DDI) studies with the strong CYP3A inhibitor itraconazole or the strong CYP3A inducer rifampin demonstrated that CYP3A‐mediated metabolism was the primary contributor to overall brigatinib clearance in humans. A physiologically‐based pharmacokinetic (PBPK) model for brigatinib was developed to predict potential DDIs, including the effect of moderate CYP3A inhibitors or inducers on brigatinib pharmacokinetics (PK) and the effect of brigatinib on the PK of transporter substrates. The developed model was able to predict clinical DDIs with itraconazole (area under the plasma concentration–time curve from time 0 to infinity [AUC ∞ ] ratio [with/without itraconazole]: predicted 1.86; observed 2.01) and rifampin (AUC ∞ ratio [with/without rifampin]: predicted 0.16; observed 0.20). Simulations using the developed model predicted that moderate CYP3A inhibitors (e.g., verapamil and diltiazem) may increase brigatinib AUC ∞ by ~40%, whereas moderate CYP3A inducers (e.g., efavirenz) may decrease brigatinib AUC ∞ by ~50%. Simulations of potential transporter‐mediated DDIs predicted that brigatinib may increase systemic exposures (AUC ∞ ) of P‐gp substrates (e.g., digoxin and dabigatran) by 15%–43% and MATE1 substrates (e.g., metformin) by up to 29%; however, negligible effects were predicted on BCRP‐mediated efflux and OCT1‐mediated uptake. The PBPK analysis results informed dosing recommendations for patients receiving moderate CYP3A inhibitors (40% brigatinib dose reduction) or inducers (up to 100% increase in brigatinib dose) during treatment, as reflected in the brigatinib prescribing information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsOrganophosphorus CompoundsPyrimidinesHumansRifampinCytochrome P-450 CYP3A InhibitorsItraconazoleCytochrome P-450 CYP3AATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsCytochrome P-450 CYP3A InducersDrug InteractionsMembrane Transport ProteinsReceptor Protein-Tyrosine KinasesModels, Biological

Substanzen

RifampinCytochrome P-450 CYP3A InhibitorsbrigatinibItraconazoleCytochrome P-450 CYP3AATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsCytochrome P-450 CYP3A InducersMembrane Transport ProteinsReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Clinical Pharmacology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
  • Simcyp Division, Certara UK Limited, Sheffield, South Yorkshire, UK.
  • Clinical Pharmacology, Cerevel Therapeutics, Cambridge, Massachusetts, USA.
  • Global DMPK, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
  • DMPK & Preclinical Safety, Theseus Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Clinical Science, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.

ORCID-Profile: Michael J Hanley, Karen Rowland Yeo, Karthik Venkatakrishnan, Neeraj Gupta

Zitieren

APA

Hanley, M. J., Yeo, K. R., Tugnait, M., Iwasaki, S., Narasimhan, N., Zhang, P., Venkatakrishnan, K., & Gupta, N. (2024). Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13106

Vancouver

Hanley MJ, Yeo KR, Tugnait M, Iwasaki S, Narasimhan N, Zhang P, et al. Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13106

BibTeX
@article{Hanley2024,
  author = {Hanley, Michael J and Yeo, Karen Rowland and Tugnait, Meera and Iwasaki, Shinji and Narasimhan, Narayana and Zhang, Pingkuan and Venkatakrishnan, Karthik and Gupta, Neeraj},
  title = {Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13106}
}
Kostenlos starten →